Metabolic & Endocrine
Growth Hormone Deficiency
48
Pipeline Programs↗
13
Active Trials↗
23
Companies Involved↗
Growth Hormone Deficiency is a moderately active landscape with 48 programs across 23 companies. The most active players are Phage Pharmaceuticals, Inc., Teva, Hanmi Pharmaceutical Company Limited. 4 therapies are approved with 20 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical6
Phase 14
Phase 214
Phase 320
Analysis
Trial Status
94
clinical trials
Completed54 · 57%
Unknown status13 · 14%
Terminated12 · 13%
Not yet recruiting5 · 5%
Enrolling by invitation5 · 5%
Withdrawn2 · 2%
Other3 · 3%
Clinical Trials
Trial Activity
94 trials
A Study of GenSci134 in Children With Growth Hormone Deficiency (PGHD)
Not yet recruiting·
Changchun GeneScience Pharmaceutical Co., Ltd.·Phase 1/2·NCT07450001·128 enrolled
Changchun GeneScience Pharmaceutical Co., Ltd.·Phase 1/2·NCT07450001·128 enrolled
Page 1 of 7
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)